Sprout Health review: pricing and terms

What Sprout Health says

These are attributed first-party merchant statements, not neutral medical evidence:

• Sprout Health says compounded semaglutide and tirzepatide are prescribed by U.S.-licensed clinicians and delivered to the patient.¹
• Sprout Health says GLP-1 medications require a prescription and are provided only when clinically appropriate.¹
• Sprout Health says results are not guaranteed and vary from person to person.¹

Reported plan and billing information

UNKNOWN exact first-month cash charge or initial checkout total. The assigned landing URL reports an as-low-as $110/month rate on a six-month plan. This is a conditional advertised monthly rate, not proof of a $110 first payment or a confirmed total upfront charge. Medication-specific applicability, payment schedule and renewal amount for that offer are not resolved by the headline. No multiplication into a purported checkout total and no zero-price inference are made. Reported starting monthly prices: compounded semaglutide $149, compounded tirzepatide $199, Wegovy $1799 and Zepbound $1999. These are product-specific starting prices, not exact initial or recurring charges for a selected plan. They are not interchangeable with the separate $110/month six-month headline. Exact customer-specific renewal prices, term and dose conditions remain UNKNOWN without the selected checkout disclosure. The brand tags are supported by explicit product offer cards, not ingredient comparisons; availability for any individual patient is not guaranteed.

Map Sprout’s delivery chain before comparing convenience

Reported information: the FAQ says orders typically ship within 3-7 business days after the clinician issues a prescription. This is a dispatch timeframe, not a guaranteed arrival date. The same capture's headline says Ships in 2-3 days, while the captured how-it-works page also states 3-7 business days. The discrepancy remains explicit; no guaranteed end-to-end delivery time is asserted. Reported information: the provider's notice lists Foothills Pharmacy and Promise Pharmacy as external-service contacts, alongside MD Integrations. This is not confirmation that either pharmacy dispenses every listed medication or fulfills a particular patient order. Exact dispensing assignment, 503A/503B classification and independently verified licensure are UNKNOWN. The product evidence separately identifies compounded semaglutide and compounded tirzepatide; no pharmacy certification or drug-approval status is inferred. Reported information: cancellation requests must be received at least 48 hours before the next billing date to avoid that charge; later requests take effect the following cycle. Cancellation stops future charges and does not refund orders already sent to the pharmacy. This is more specific than the landing page's cancel-anytime headline. These are the provider's consumer terms, not affiliate-program terms or a legal determination.

Sprout’s appropriateness language limits the claim

The merchant states that GLP-1 medication requires a prescription and is provided only when clinically appropriate. That is an important boundary: it describes a conditional process rather than guaranteed access. It does not define eligibility criteria, establish that a particular drug will be offered, or predict whether a clinician will prescribe after review. It also does not turn compounded semaglutide or tirzepatide into FDA-approved products. For consumer research, the useful questions concern process transparency: who reviews the case, what information is required, whether another product may be proposed, and what financial terms apply if treatment is not prescribed. Those questions preserve the clinician’s role while letting a reader evaluate the service contract. Suitability, product choice, dosing, contraindications, and monitoring are outside the scope of this editorial review.

What to document if Sprout answers the open terms

Before paying, request a written breakdown of the first charge and recurring charge, cadence, medication, supply duration, clinical visits, shipping, laboratory work if any, refill handling, cancellation deadline, and refund policy. Also ask for current state availability and the dispensing-pharmacy identity applicable to the prescription pathway. Keep the response with its date rather than assuming an answer remains permanent. If the $149 amount applies only under a condition, record that condition beside the price instead of presenting the figure alone. This checklist is deliberately commercial and operational; it makes no recommendation about treatment. Its purpose is to prevent a starting-price banner and broad delivery statement from carrying more evidentiary weight than they deserve when Sprout is compared with another provider.

Pricing and billing

UNKNOWN exact first-month cash charge or initial checkout total. The assigned landing URL reports an as-low-as $110/month rate on a six-month plan. This is a conditional advertised monthly rate, not proof of a $110 first payment or a confirmed total upfront charge. Medication-specific applicability, payment schedule and renewal amount for that offer are not resolved by the headline. No multiplication into a purported checkout total and no zero-price inference are made. Reported starting monthly prices: compounded semaglutide $149, compounded tirzepatide $199, Wegovy $1799 and Zepbound $1999. These are product-specific starting prices, not exact initial or recurring charges for a selected plan. They are not interchangeable with the separate $110/month six-month headline. Exact customer-specific renewal prices, term and dose conditions remain UNKNOWN without the selected checkout disclosure. The brand tags are supported by explicit product offer cards, not ingredient comparisons; availability for any individual patient is not guaranteed. Reported information: the refund policy deducts a flat $50 clinical-review fee only after provider review and before the prescription is sent to the pharmacy. Before review it states full refund; after pharmacy submission it states non-refundable. The $50 is a conditional refund deduction, not evidence of a standard additional upfront consultation charge. The separately quoted checkout-inclusion statement is bound in provider_dynamic_profile. The consultation's standalone price remains UNKNOWN, not zero.¹

Clinician and prescription boundary

Sprout Health's first-party description says prescription treatment is considered only when clinically appropriate. That does not establish eligibility or guarantee a prescription. A licensed clinician must make prescribing and treatment decisions; this review gives no individualized recommendation or dosing advice.¹

Compounded-drug and FDA status

The page describes compounded semaglutide and tirzepatide, which are distinct from FDA-approved branded drugs. Compounded drugs are not FDA approved, and FDA does not premarket-review them for safety, effectiveness, or quality.²

What remains unknown

• UNKNOWN exact first-month cash charge or initial checkout total. The assigned landing URL reports an as-low-as $110/month rate on a six-month plan. This is a conditional advertised monthly rate, not proof of a $110 first payment or a confirmed total upfront charge. Medication-specific applicability, payment schedule and renewal amount for that offer are not resolved by the headline. No multiplication into a purported checkout total and no zero-price inference are made. Reported starting monthly prices: compounded semaglutide $149, compounded tirzepatide $199, Wegovy $1799 and Zepbound $1999. These are product-specific starting prices, not exact initial or recurring charges for a selected plan. They are not interchangeable with the separate $110/month six-month headline. Exact customer-specific renewal prices, term and dose conditions remain UNKNOWN without the selected checkout disclosure. The brand tags are supported by explicit product offer cards, not ingredient comparisons; availability for any individual patient is not guaranteed.
• Reported information: the FAQ says orders typically ship within 3-7 business days after the clinician issues a prescription. This is a dispatch timeframe, not a guaranteed arrival date. The same capture's headline says Ships in 2-3 days, while the captured how-it-works page also states 3-7 business days. The discrepancy remains explicit; no guaranteed end-to-end delivery time is asserted. Reported information: cancellation requests must be received at least 48 hours before the next billing date to avoid that charge; later requests take effect the following cycle. Cancellation stops future charges and does not refund orders already sent to the pharmacy. This is more specific than the landing page's cancel-anytime headline. These are the provider's consumer terms, not affiliate-program terms or a legal determination.
• No comparable independent public-review dataset was captured.
• No evidence supports an efficacy promise, outcome guarantee, or individualized recommendation.